| Ms Linda Marie Palladino, LICSW | |
|
950 Cambridge St, Cambridge, MA 02141-1001 | |
| (617) 441-1805 | |
| Not Available |
| Full Name | Ms Linda Marie Palladino |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 950 Cambridge St, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073641627 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | 1028292 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Linda Marie Palladino, LICSW 61 W Elm St, Hopkinton, MA 01748-2126 Ph: (508) 497-8924 | Ms Linda Marie Palladino, LICSW 950 Cambridge St, Cambridge, MA 02141-1001 Ph: (617) 441-1805 |
News Archive
"Most African countries are lagging behind in achieving the United Nations' Millennium Development Goals [MDGs] and will not make as much progress in health, nutrition and sanitation as had hoped, U.N. officials said" on Thursday, the Associated Press/ABC News reports.
The woman chosen to represent the legal challenge to the Obama administration's health care overhaul filed for bankruptcy in September after her business failed, a move that could pose problems for the high-profile lawsuit. … The suit, brought by 26 states and joined by the National Federation of Independent Business, a small-business lobby group, is set to be heard by the Supreme Court next year.
Capsugel is launching an innovative capsule design to improve adherence to treatment regimens for patients with difficulties swallowing. These patients include babies, children, and older adults as well as patients with medical conditions such as Alzheimer's, Parkinson's, and Multiple Sclerosis. The new Coni-Snap sprinkle capsule is expected to be available in 2014.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
› Verified 8 days ago
Glorimar Gonzalez-raices, Counselor Medicare: Not Enrolled in Medicare Practice Location: 20 Dudley St, Cambridge, MA 02140 Phone: 413-265-4794 | |
Ms. Gopi Dhokai, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 545 Concord Ave Ste 14, Cambridge, MA 02138 Phone: 240-506-9768 | |
Marisa Anderson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1158 Massachusetts Ave Fl 3, Cambridge, MA 02138 Phone: 857-314-0554 | |
Mr. Pavan S. Brar, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St Rm 239, Cambridge, MA 02139 Phone: 617-575-5399 | |
Carlos Suarez, M.A. Counselor Medicare: Not Enrolled in Medicare Practice Location: 5 Sacramento St, Cambridge, MA 02138 Phone: 617-354-2275 Fax: 617-547-4356 | |
Susan M Dingsor, Counselor Medicare: Not Enrolled in Medicare Practice Location: 350 Cambridge St, Cambridge, MA 02141 Phone: 617-547-0909 | |
Suad N Warsame, Counselor Medicare: Not Enrolled in Medicare Practice Location: 52 Trowbridge St Apt 11, Cambridge, MA 02138 Phone: 617-270-1725 |